# XERIS BIOPHARMA HOLDINGS, INC. (XERS) FY2026 Q2 Balance Sheet

- Company: XERIS BIOPHARMA HOLDINGS, INC. (XERS)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001867096-26-000065
- Page: https://plicit.ai/financials/xers/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/xers-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 411,905,000 US dollars
- **Current assets**: 274,757,000 US dollars
- **Non-current assets**: 137,148,000 US dollars
- **Liabilities**: 421,639,000 US dollars
- **Current liabilities**: 189,568,000 US dollars
- **Non-current liabilities**: 232,071,000 US dollars
- **Equity**: negative 9,734,000 US dollars
- **Cash and cash equivalents**: 121,747,000 US dollars
- **Inventory, net**: 80,930,000 US dollars
- **Trade accounts receivable, net**: 58,105,000 US dollars
- **Prepaid expenses and other current assets**: 13,975,000 US dollars
- **Other assets**: 82,657,000 US dollars
- **Goodwill**: 22,859,000 US dollars
- **Operating lease right-of-use assets**: 21,773,000 US dollars
- **Other assets**: 5,025,000 US dollars
- **Property and equipment, net**: 4,834,000 US dollars
- **Current portion of long-term debt**: 63,783,000 US dollars
- **Accrued trade discounts and rebates**: 46,858,000 US dollars
- **Other accrued liabilities**: 39,706,000 US dollars
- **Accrued returns reserve**: 18,598,000 US dollars
- **Accounts payable**: 9,337,000 US dollars
- **Current operating lease liabilities**: 6,310,000 US dollars
- **Other current liabilities**: 4,976,000 US dollars
- **Debt, net of unamortized debt issuance costs, non-current portion**: 188,807,000 US dollars
- **Non-current operating lease liabilities**: 30,542,000 US dollars
- **Other liabilities**: 12,722,000 US dollars
- **Additional paid in capital**: 690,432,000 US dollars
- **Common stock—par value $0.0001, 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,591,637 and 166,215,410 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively**: 18,000 US dollars
- **Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 700,174,000 US dollars
- **Accumulated other comprehensive loss**: negative 10,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.